The study, led by Meili Yu and colleagues at the Affiliated Taian City Central Hospital of Qingdao University, enrolled 32 patients with central-type lung cancer complicated by atelectasis who had either contraindications to bronchoscopy or in whom the procedure had failed. All were scanned and biopsied under contrast-enhanced ultrasound guidance between February 2022 and February 2025. The central question was deceptively simple: on a grayscale ultrasound image, can you actually tell where the tumor ends and the collapsed lung begins? If you cannot, any needle trajectory is a guess, and a guess that samples collapsed, inflamed, or necrotic tissue yields a false negative or a useless specimen.

The answer to that question is where the technique earns its keep. With conventional ultrasound alone, the interface between tumor and adjacent atelectatic lung was visible in only 40.6 percent of the patients, meaning that in nearly six out of ten cases the operator was effectively navigating blind. After an intravenous injection of an ultrasound contrast agent, that display rate jumped to 96.9 percent. In the 31 patients in whom the tumor-lung interface became clearly delineated, the enhancement dynamics themselves carried diagnostic information, because tumor tissue and collapsed lung tissue perfuse at measurably different speeds and with different patterns.

Those dynamics follow a consistent physiological logic. Lung cancers of the central type draw their blood supply from the bronchial arterial circulation, and the study found that all of the malignant lesions began to enhance between 10 and 17 seconds after contrast injection. The atelectatic lung, by contrast, is fed largely by the pulmonary arterial system, and in 80.7 percent of cases, 25 of the 31 evaluable patients, the collapsed tissue lit up earlier than the tumor. That timing difference gives the operator a real-time map: the region that enhances late is the tumor, the region that enhances early is the collapsed lung, and the needle can be steered toward the late-enhancing territory with a confidence that grayscale imaging cannot provide.

The enhancement pattern over time added a second layer of discrimination. In 83.9 percent of patients, 26 of 31, the central tumors showed what radiologists describe as a slow-in, fast-out pattern: contrast arrived late relative to the surrounding collapsed lung and then washed out quickly, a signature of the disorganized, arteriovenous-shunting microvasculature typical of malignant tissue. In 90.3 percent of lesions, 28 of 31, the tumor ultimately appeared hypo-enhanced relative to the reference tissue, reflecting the relatively sparse and abnormal vessel density within the tumor mass compared with the hyperemic collapsed lung around it. Together, the timing, the washout behavior, and the relative intensity form a composite target signature that the operator can follow on screen.

The technique also exposed a complication that would otherwise sabotage the biopsy silently. In nine patients, 28.1 percent of the cohort, the contrast scan revealed entirely non-enhancing areas within the lesion, corresponding to necrotic tissue where no viable tumor cells would be found. Sampling a necrotic core is one of the classic causes of non-diagnostic biopsies, and conventional imaging frequently cannot distinguish necrosis from viable tumor. By marking the non-enhancing zones in real time, the CEUS approach allowed the operators to aim for the enhancing, viable rim instead, which is precisely the material a pathologist needs to render a definitive diagnosis.

The bottom line for the 31 patients with a clearly visualized target was unambiguous: every single one underwent a successful puncture and yielded a definite pathological diagnosis. In a population defined by the failure or impossibility of the standard first-line diagnostic route, a 100 percent diagnostic sampling rate is a striking result. Equally important for a technique that involves passing a needle through the chest wall toward the mediastinum, the study reported no severe puncture-related complications, suggesting that the real-time vascular mapping provided by contrast enhancement does not merely improve yield but may also contribute to procedural safety by keeping the needle away from vessels and necrotic cavities.

Placed in context, the findings address a genuine clinical bottleneck. Central-type lung cancers arise in the large central airways, where bronchoscopic visualization and forceps biopsy are normally straightforward, which is why bronchoscopy dominates diagnostic algorithms for this tumor location. But the same tumors frequently obstruct the bronchus enough to collapse the downstream lung, and the resulting atelectasis creates a consolidated, fluid-filled region on ultrasound that can look remarkably similar to the tumor itself. Patients who cannot be bronchoscoped, whether because of respiratory failure, coagulopathy, vascular anatomy, or a failed attempt, have historically faced repeated attempts, more invasive surgical biopsies, or empiric treatment without histology. A percutaneous, ultrasound-guided alternative that works at the bedside, avoids ionizing radiation, and exploits the perfusion contrast between tumor and collapsed lung offers a pragmatic escape route.

The study’s design and scale warrant measured interpretation. It was retrospective, single-center, and involved 32 patients over a three-year window, and the authors themselves frame the work as an exploration of diagnostic value rather than a definitive trial. Selection is a consideration: these were patients in whom the technique was attempted, and the learning curve for CEUS-guided thoracic biopsy is real, since the operator must interpret contrast kinetics in real time while advancing a needle. The enhancement timings reported here, with tumors enhancing at 10 to 17 seconds and atelectatic lung typically earlier, provide a useful reference range, but they derive from one institution’s experience with one contrast agent and one scanner platform. Broader, ideally prospective, multicenter validation would be needed before the approach becomes a standard recommendation in guidelines.

Even with those caveats, the study adds a technically elegant tool to a problem that has few good answers. Contrast-enhanced ultrasound is inexpensive relative to CT or PET guidance, portable enough to be performed in an interventional suite or at the bedside, and free of the radiation burden of repeated CT-guided passes. By converting the perfusion differences between a tumor and the collapsed lung surrounding it into a visible, time-resolved map, the technique turns a previously ambiguous grayscale field into a target with defined borders, defined timing, and defined zones of viability. For the subset of lung cancer patients who are too sick or too difficult to bronchoscope, that transformation may be the difference between a specimen that changes treatment and a diagnostic dead end. The Taian team’s data, showing near-universal interface visualization, consistent tumor enhancement signatures, and complete diagnostic success without severe complications, make a credible case that CEUS-guided percutaneous biopsy deserves a defined place in the diagnostic algorithm for central lung cancer with atelectasis.

Subject of Research: Contrast-enhanced ultrasound-guided percutaneous biopsy for diagnosing central-type lung cancer with atelectasis in patients with bronchoscopy contraindications or failure

Article Title: Application of Contrast-Enhanced Ultrasound (CEUS)-guided percutaneous biopsy in the diagnosis of central-type lung cancer patients with bronchoscopy contraindications or failed

Article References: Yu, M., Zheng, Y., Zhang, M., Wang, L., Lyu, G., Zhang, C., & Liu, B. (2026). Application of Contrast-Enhanced Ultrasound (CEUS)-guided percutaneous biopsy in the diagnosis of central-type lung cancer patients with bronchoscopy contraindications or failed. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02840-z

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02840-z

Keywords: contrast-enhanced ultrasound, CEUS, lung cancer, central-type lung cancer, atelectasis, percutaneous biopsy, bronchoscopy, tumor-lung interface, interventional radiology, cancer imaging, diagnostic biopsy, BMC Medical Imaging

The scientific premise behind the work is deceptively simple. If some primary tumors are intrinsically competent to spread, then the cells within those tumors should express a recurring set of genes that distinguishes them from tumors that remain indolent. To find that set, the researchers aggregated gene-expression data from six independent cohorts of primary prostate tumors, encompassing 1,000 patients and 306 documented metastatic events. Rather than pooling raw data, they applied a random-effects meta-analysis, a statistical framework that estimates a pooled effect size for each gene while explicitly accounting for between-study heterogeneity. For every gene, they computed Hedges’ g, a standardized measure of effect magnitude, along with Cochran’s Q and the I-squared statistic to quantify how consistently the effect held across studies. Genes were retained only if their direction of change was reproducible, yielding a 45-gene metastatic progression program: 27 genes up-regulated and 18 down-regulated in tumors that ultimately metastasized.

With the signature defined, the team converted it into a clinically deployable instrument. They trained an L2-regularized logistic regression model, a form of ridge regression that penalizes large coefficients to prevent overfitting, using the 45 genes as predictors and metastatic progression as the outcome. Crucially, the model coefficients were locked once trained and then applied unchanged to completely independent validation cohorts, with no per-cohort refitting. This frozen-deployment design is a rigorous test of generalizability, because many biomarker studies quietly recalibrate their models to each new dataset, inflating apparent performance. In the Johns Hopkins Natural History cohort of 239 patients with 93 metastatic events, the locked Met-Score achieved competing-risk time-dependent AUCs of 0.75 at five years and 0.71 at ten years. In the Durham Veterans Affairs cohort of 555 patients with 40 events, the corresponding AUC was 0.79 at both time horizons. A pooled meta-analytic AUC across the development cohorts reached 0.81.

Discrimination alone is not enough; a biomarker must add information beyond what clinicians already measure. The investigators therefore tested whether Met-Score remained associated with metastasis-free survival after adjustment for pathological Gleason grade, the standard histologic measure of tumor aggressiveness. It did, in both validation cohorts. Even more intriguing were exploratory analyses confined to Gleason 7 disease, the large and clinically ambiguous middle category where treatment decisions are most contested. Within this group, Met-Score appeared to resolve additional risk beyond Grade Group alone, suggesting that two men with histologically identical tumors could carry very different metastatic potentials. The authors are careful to note that this finding requires prospective confirmation, but it points toward a future in which transcriptomic profiling could spare low-risk patients aggressive therapy while intensifying surveillance for those whose tumors carry a hidden program of spread.

The signature also proved its worth on diagnostic biopsy material, which is what clinicians actually have in hand at diagnosis. In cross-sectional RNA-sequencing cohorts of diagnostic biopsies, Met-Score separated de novo metastatic, hormone-naïve disease from localized disease with striking accuracy, achieving AUCs between 0.93 and 0.98. This is a critical technical point: a biomarker that only works on surgically resected prostatectomy specimens is of limited use for risk stratification at the moment of decision-making. The biopsy results indicate that the metastatic competence program is detectable in the small amount of tissue obtained through a needle, supporting the idea that the biology of spread is present from the outset rather than acquired only late in the disease course.

To understand where in the tumor ecosystem the signature resides, the researchers turned to single-cell RNA sequencing of tumor biopsies spanning localized disease, metastatic hormone-sensitive disease, and metastatic castration-resistant disease. The analysis revealed that tumor cells in metastatic disease carried significantly higher Met-Score activity than tumor cells in localized tumors, with the signal concentrated in proliferative transcriptional programs. Equally notable was the cell-type-restricted expression pattern of the component genes: individual genes within the signature were expressed in markedly different cellular compartments, meaning the composite score integrates both malignant-cell-intrinsic programs and features of the surrounding microenvironment. This decomposition matters because it reframes metastatic competence not as a property of tumor cells alone but as a coordinated transcriptional state spanning multiple cell populations.

The bone metastatic niche provided a second vantage point. In a dataset examining bone marrow and bone metastasis samples, Met-Score showed cell-type-specific enrichment in tumor tissue relative to distal marrow, with particularly strong signal among lymphoid populations. This observation hints that the immune and stromal composition of the metastatic niche may echo, or even support, the transcriptional program measured in the primary tumor. Whether the signature reflects a pre-adaptation of the tumor, a permissive niche, or both remains an open question, but the concordance across anatomical sites strengthens the case that Met-Score captures a conserved biological program rather than a cohort-specific artifact.

Perhaps the most forward-looking result concerns therapeutic responsiveness. In a patient-derived xenograft model of metastatic bone disease, Met-Score declined after treatment with batiraxcept, an agent targeting the AXL-ALK and related signaling axis, and the score shifted concordantly across independent genetic and pharmacologic perturbation datasets. In practical terms, this means the transcriptional program is not a fixed, inert label; it moves when the underlying biology is pushed. A biomarker that responds to perturbation can in principle serve as a pharmacodynamic readout, allowing researchers to test whether candidate therapies actually dismantle the metastatic competence state in early-phase trials, long before survival endpoints mature.

The study also subjected its own construction to unusually thorough robustness testing. A leave-one-cohort-out sensitivity analysis recomputed per-gene statistics after iteratively excluding each discovery cohort, confirming that effect directions and significance were stable. Nested internal-external cross-validation compared the full 45-gene ridge model against trimmed top-10 and top-20 variants, LASSO, and elastic net alternatives, and the frozen signature held its performance against models retrained from scratch. Secondary endpoints in the Durham VA cohort, including prostate cancer-specific mortality, overall survival, and biochemical recurrence, were analyzed with competing-risk methods, and decision-curve analyses evaluated the clinical net benefit of adding Met-Score to a baseline model of Grade Group, PSA, and pathological T stage. Sensitivity analyses addressed tumor purity, race-specific effects, landmark times, and adjustment for a cell-cycle progression gene score, all of which the association between Met-Score and metastasis survived.

Caveats remain, and the authors state them plainly. The Gleason 7 findings are exploratory; the validation cohorts, while independent, are retrospective; and the model was trained on bulk expression data whose biological interpretation depends on the single-cell and perturbation analyses that support it. Prospective evaluation will be required before Met-Score can inform treatment decisions. Even so, the convergence of evidence is compelling: a reproducible, biologically interpretable, 45-gene program detectable in primary tumors and diagnostic biopsies, enriched in proliferative tumor cells, reflected in the metastatic niche, and responsive to therapeutic perturbation. If prospective trials confirm its value, Met-Score could shift prostate cancer risk stratification from a discipline of looking backward at histology toward one of reading forward from the tumor’s own transcriptional blueprint, identifying at diagnosis which cancers carry the seeds of metastasis and which do not.

Subject of Research: A transcriptomic biomarker for predicting metastatic progression in primary prostate cancer

Article Title: A conserved metastatic competence signature from primary prostate tumors

Article References: Valencia, I., Vasanthakumari, P., Aghmiouni, M. R., Magana, B., Nuzzo, P. V., Kim, M., Francini, E., Ravera, F., Fanelli, G. N., Bleve, S., Scatena, C., Marchionni, L., Freedland, S. J., You, S., & Omar, M. (2026). A conserved metastatic competence signature from primary prostate tumors. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09046-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09046-5

Keywords: prostate cancer, metastasis, Met-Score, gene expression signature, biomarker, risk stratification, transcriptomics, single-cell RNA sequencing, tumor microenvironment, Gleason grade, diagnostic biopsy, prognostic marker